ROCHELLE, Va., July 11, 2018 /PRNewswire-PRWeb/ -- NDA Partners Chairman Carl Peck, MD,
Prior to joining NDA Partners, Dr. Schense served as Chief Technology Officer, Kuros Biosciences AG, where he was responsible for the company's R&D. He is a founder of Kuros Biosurgery AG (now Kuros Biosciences AG) and successfully lead the startup into product development, then transitioned into project management and executive management serving as the Executive Director, Spine & Trauma.
"Dr. Schense's extensive experience in the pharmaceutical and medical device fields in European and US regulatory strategy, development strategy, clinical study design, and program management, in addition to his strong technical background in regenerative medicine working on medical devices, drugs, and combination products, makes him an excellent addition to our team of Expert Consultants," said Dr. Peck. "We are very pleased to welcome him to NDA Partners."
Dr. Schense earned his doctorate and Master of Science degree from the California Institute of Technology's Department of Chemical Engineering and a Bachelor of Science degree in Chemical Engineering from Massachusetts Institute of Technology. He conducted his postdoctoral research at ETH Zurich's Department of Materials in Biomedical Engineering.
About NDA Partners NDA Partners is a life sciences management consulting firm focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and management of client product development programs.
Contact Earle Martin, Chief Executive Officer Office: 540-738-2550 MartinEarle(at)ndapartners(dot)com
SOURCE NDA Partners, LLC
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All